Antoniou Katerina M, Karagiannis Konstantinos, Tsitoura Eliza, Bibaki Eleni, Lasithiotaki Ismini, Proklou Athanasia, Spandidos Demetrios A, Tzanakis Nikos
Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion 71110, Crete, Greece.
Department of Thoracic Medicine, Interstitial Lung Disease Unit, University Hospital, University of Crete, Heraklion 71110, Crete, Greece.
Biomed Rep. 2018 Apr;8(4):314-318. doi: 10.3892/br.2018.1067. Epub 2018 Feb 16.
Mesenchymal stem (stromal) cells (MSCs) are multipotent stromal cells that have the ability to modulate immune response to tissue injury and promote repair . The therapeutic potential of expanded MSCs are currently under investigation for a variety of chronic and acute lung diseases. This review summarizes the encouraging results regarding the safety of MSCs administration from recent and current clinical trials for idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and chronic obstructive pulmonary disease. It also reviews the early preliminary data extracted by the same trials regarding the efficacy of MSCs in the aforementioned lung diseases.
间充质干细胞（MSC）是多能基质细胞，具有调节对组织损伤的免疫反应并促进修复的能力。目前正在研究扩增后的MSC对多种急慢性肺部疾病的治疗潜力。本综述总结了近期和当前针对特发性肺纤维化、急性呼吸窘迫综合征和慢性阻塞性肺疾病的临床试验中有关MSC给药安全性的令人鼓舞的结果。它还回顾了这些试验提取的关于MSC在上述肺部疾病中疗效的早期初步数据。
